Abstract
The present study aims to develop a highly safe regenerative therapy that effectively induces periodontal tissue regeneration by targeting amelogenin and its newly associated molecule, glucose-regulated protein 78 (Grp78). The enamel matrix derivative (Emdogain® Gel, Straumann) is currently the only bioregeneration tool in use that is approved by the Japanese Ministry of Health, Labour and Welfare. However, in addition to the safety issues that exist owing to it being a foreign protein, a unified opinion on its mechanism of action at the signal transduction level remains unclear. Previously, our laboratory was the first to report the identification of a new amelogenin-associated molecule, Grp78, in osteoblasts. This association was later shown to promote the migration of periodontal ligament stem cells (PDLSCs), which play critical role in periodontal regeneration. Based on these results, we aim to establish the molecular basis for periodontal tissue regeneration via the combined use of recombinant amelogenin and inducers of Grp78 which could be applied by reapplication of existing drugs (drug repositioning).
Highlights
Many of the recent periodontal treatments have focused on tissue regeneration, and some are producing positive results
Identification of amelogenin-binding molecules in cells, such as osteoblasts and mesenchymal stem cell (MSC)-derived PDL stem cells (PDLSCs), which are important in the regeneration of periodontal tissue, was an indispensable topic of study
We found that the interaction between amelogenin and glucose-regulated protein 78 (Grp78) enhances cell proliferation in osteoblasts [12] and contribute to cell migration in PDLSCs [13]
Summary
Many of the recent periodontal treatments have focused on tissue regeneration, and some are producing positive results. EMD has already been commercialized (known commercially as Emdogain® Gel), and is currently the only substance that uses biologically active proteins for the regeneration of periodontal tissue to have been approved by the Japanese Ministry of Health, Labour and Welfare.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
